<?xml version="1.0" encoding="UTF-8"?>
<collection>
<dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:invenio="http://invenio-software.org/elements/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:identifier>doi:10.1021/acsami.5c08968</dc:identifier><dc:language>eng</dc:language><dc:creator>Mattar, Iman</dc:creator><dc:creator>Landa, Guillermo</dc:creator><dc:creator>Frutos-Lizano, Marina</dc:creator><dc:creator>Izquierdo, Natalia</dc:creator><dc:creator>Tapia, Elena</dc:creator><dc:creator>Perez, Marta</dc:creator><dc:creator>Lujan, Lluis</dc:creator><dc:creator>Irusta, Silvia</dc:creator><dc:creator>Mendoza, Gracia</dc:creator><dc:creator>Arruebo, Manuel</dc:creator><dc:title>Multifunctional 3D-Printed Wound Dressings Containing a Combination of Synergistic Antimicrobials in the Management of MRSA Infected Topical Wounds</dc:title><dc:identifier>ART-2025-145322</dc:identifier><dc:description>Despite increased pre- and postoperative care and aseptic practices in surgical rooms, methicillin-resistant Staphylococcus aureus (MRSA) continues to colonize acute surgical wounds. MRSA is also present in chronic nonhealing wounds, such as diabetic foot and pressure ulcers. In this work, advanced antimicrobial-loaded wound dressings are 3D printed using fused deposition modeling. To achieve a high antimicrobial effect, the topical antiseptic octenidine (OCT) was incorporated into the pellets used in the feeder of the extruder prior to fused modeling. Lysostaphin (LYS), a lytic enzyme that cleaves MRSA peptidoglycan, was incorporated by supramolecular interactions on the surface of the OCT-loaded dressings to exploit the anti-MRSA synergy identified here between OCT and LYS showing a fractional inhibition concentration index (FICI) of 0.156. Minimum inhibitory concentration (MIC) and bactericidal concentration (MBC) values for the OCT were 1 and 25 μg/mL, respectively, whereas the MIC and MBC values for the LYS were 0.1 and 0.2 μg/mL, respectively. The resulting dressings completely eradicate MRSA USA 300 inocula (105 CFU/mL) in 96 h. The bactericidal mechanisms exerted by these dressings were identified through molecular techniques, showing lytic effects on the cell wall peptidoglycans of treated bacteria. Additionally, OCT at 1 μg/mL was able to reduce lipopolysaccharide (100 ng/mL)-induced NO production on murine J774A.1 macrophages by more than 90% demonstrating its simultaneous anti-inflammatory action. This effect was also corroborated by the qRT-PCR analysis of several pro-inflammatory genes including IL-1β, IL-6, TNF-α, and Nos2. The combination of OCT and LYS within the dressings reveals higher in vivo therapeutic effects compared to free compounds or individual antimicrobial-loaded dressings. In vitro and in preclinical models, the use of OCT-LYS dressings effectively reduces MRSA bioburden and inflammation, promoting fast wound healing.</dc:description><dc:date>2025</dc:date><dc:source>http://zaguan.unizar.es/record/162752</dc:source><dc:doi>10.1021/acsami.5c08968</dc:doi><dc:identifier>http://zaguan.unizar.es/record/162752</dc:identifier><dc:identifier>oai:zaguan.unizar.es:162752</dc:identifier><dc:relation>info:eu-repo/grantAgreement/ES/AEI/CEX2023-001286-S</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/ISCIII/FORT23-00028</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/ISCIII/MS19-00092</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/MICINN/PID2020-113987RB-I00</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/MICINN/PID2023-146091OB-I00</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/MICINN PRE2022-105709</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/UZ/LMA-ELECMI ICTS</dc:relation><dc:identifier.citation>ACS applied materials &amp; interfaces 17, 34 (2025), 47951-47968</dc:identifier.citation><dc:rights>by</dc:rights><dc:rights>https://creativecommons.org/licenses/by/4.0/deed.es</dc:rights><dc:rights>info:eu-repo/semantics/openAccess</dc:rights></dc:dc>

</collection>